These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
86 related articles for article (PubMed ID: 3833791)
21. Type I hyperlipoproteinemia presenting as sudden death in infancy. Potter JM; Hilton JM Aust N Z J Med; 1983 Aug; 13(4):381-3. PubMed ID: 6580863 [TBL] [Abstract][Full Text] [Related]
22. [Hyperlipoproteinemia mass screening in a pediatric patient group]. László A; Joó I; Turi S Kinderarztl Prax; 1982 Oct; 50(10):506-17. PubMed ID: 7154521 [No Abstract] [Full Text] [Related]
23. No prescription for despair. Robinson A CMAJ; 1993 Sep; 149(5):639-43. PubMed ID: 8364820 [No Abstract] [Full Text] [Related]
24. [Effective long-term treatment of primary hyperlipoproteinemias with bezafibrate]. Schiffl H; Weidmann P; Fragiacomo C; Noseda G; Bachmann C Schweiz Med Wochenschr; 1985 Jun; 115(26):907-11. PubMed ID: 3927481 [TBL] [Abstract][Full Text] [Related]
25. [Classification of hyperlipoproteinemia in the light of advances in pathogenetic studies]. Pometta D; James RW; Leowski J; Packard CJ; Shepherd J Pol Tyg Lek; 1985 Dec; 40(50):1389-94. PubMed ID: 3831987 [No Abstract] [Full Text] [Related]
26. [How should primary hyperlipoproteinemia be classified?]. Rubiés-Prat J Med Clin (Barc); 1983 May; 80(19):836-8. PubMed ID: 6888036 [No Abstract] [Full Text] [Related]
33. [The incidence and course of glucose tolerance disorder in familial hyperlipoproteinemia]. Kolesár P Vnitr Lek; 1985 Jan; 31(1):20-6. PubMed ID: 3969786 [No Abstract] [Full Text] [Related]
34. [The therapeutic efficacy of bezafibrate in hyperlipoproteinemias of various types]. Noseda G; Fragiacomo C; Weidmann P; Bachmann C Schweiz Med Wochenschr; 1980 Dec; 110(49):1875-7. PubMed ID: 7455660 [TBL] [Abstract][Full Text] [Related]
35. [Gene mutations responsible for hyperlipoproteinemia]. Sato R; Okabayashi M; Kajinami K Nihon Rinsho; 2007 Jul; 65 Suppl 7():115-9. PubMed ID: 17824022 [No Abstract] [Full Text] [Related]
36. Apolipoprotein C-II deficiency presenting as a lipid encephalopathy in infancy. Wilson CJ; Priore Oliva C; Maggi F; Catapano AL; Calandra S Ann Neurol; 2003 Jun; 53(6):807-10. PubMed ID: 12783430 [TBL] [Abstract][Full Text] [Related]
37. Hemorrheologic abnormalities in defined primary dyslipoproteinemias with both high and low atherosclerotic risks. Otto C; Ritter MM; Richter WO; Minkenberg R; Schwandt P Metabolism; 2001 Feb; 50(2):166-70. PubMed ID: 11229424 [TBL] [Abstract][Full Text] [Related]
38. Emotional implications of primary familial hyperlipoproteinemia in childhood and adolescence. Froese AP; Rose V; Allen DM Pediatrics; 1980 Mar; 65(3):469-72. PubMed ID: 7360532 [TBL] [Abstract][Full Text] [Related]
39. Absence of apolipoprotein B3500 mutation in type 2a hyperlipoproteinemia patients and in the general population from southern Italy. Seripa D; Gravina C; Volpe R; Margaglione M; Papa S; Merla G; Parrella P; Di Minno G; Ricci G; Testa M; Fazio VM J Inherit Metab Dis; 1999 Jun; 22(5):670-1. PubMed ID: 10399102 [No Abstract] [Full Text] [Related]
40. [Plasma lipoproteins. Influence of heredity and external factors in the genesis of dyslipidemias]. Pometta D Rev Med Suisse Romande; 1980 Jan; 100(1):33-7. PubMed ID: 7384670 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]